Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase <scp>III</scp>, Double‐Blind, Randomized Controlled Trial

Fleischmann, Roy; L. Pangan, Aileen; Song, In‐Ho; Mysler, Eduardo; Bessette, Louis; Peterfy, Charles; Durez, Patrick; J.K. Östör, Andrew; Li, Yihan; Zhou, Yijie; A. Othman, Ahmed; C. Genovese, Mark

doi:10.1002/art.41032

Public

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double‐Blind, Randomized Controlled Trial

Published in Arthritis & Rheumatology • Jul 9, 2019

Authors:

Roy Fleischmann

Aileen L. Pangan

In‐Ho Song

Abstract

OBJECTIVE: To evaluate the efficacy, including capacity for inhibition of radiographic progression, and safety of upadacitinib, a JAK1-selective inhibitor, as compared to placebo or adalimumab in patients with rheumatoid arthritis (RA) who have experienced an inadequate response to methotrexate (MTX...

Subject

Medicine

Adalimumab

Rheumatoid arthritis

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!